Compounds can be used for treating polycystic kidney disease (PKD). As such, these compounds can be used in associated methods. The methods can include: method of modulating (e.g., activating) Liver kinase B1 (LKB1); method of modulating (e.g., decreasing activity) mammalian target of rapamycin (mTOR). The methods may include introducing the compound in a therapeutically effective amount to a subject having PKD. The methods may include introducing the compound in a therapeutically effective amount to a subject having Autosomal Dominant PKD. The compounds can be used in methods of treating a disease modulated by a mTOR pathway, which can include introducing the compound in a therapeutically effective amount to a subject having the disease modulated by the mTOR pathway. The disease modulated by mTOR is selected from the group consisting of multiple types of cancer, including breast cancer, renal cell carcinoma, colorectal cancer, prostate cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, skin cancer, glioblastoma, bone metastatic cancer, head and neck cancer, and leukemia, kidney disease, obesity, neuro disorders and alcohol-related chronic diseases.

The University of Kansas

LKB1-AMPK activators for therapeutic use in polycystic kidney disease

The present invention relates to mannose derivatives of formula (I): ##STR00001## wherein R.sub.1 represents H, CO--(C.sub.1-C.sub.6)-alkyl or CO-alkylaryl, Y represents a single bond, CH.sub.2, O, NR.sub.3, S, A represents O, NH or S, X represents H and X' represents OH or X and X' taken together with the carbon atom bearing them form a CO group, R.sub.2 represents H, a linear or branched (C.sub.1-C.sub.6)-alkyl or CF.sub.3, R.sub.3 represents H, a C.sub.1-C.sub.6 alkyl, a CO--(C.sub.1-C.sub.6)-alkyl, CF.sub.3 or COCF.sub.3, and R is as described in claim 1. The mannose derivatives of formulae (I) are useful for treating pathologies associated with the presence of adherent Escherichia coli (AEC), in particular inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; a urinary tract infection, in particular painful bladder syndrome and cystitis, more particularly interstitial cystitis; irritable bowel syndrome; metabolic diseases such as metabolic obesity, diabetes, hypercholesterolemia; autoimmune inflammatory diseases; and colorectal cancer, in particular colon cancer.

ENTEROME

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

UNIVERSITE CLERMONT AUVERGNE

UNIVERSITE DE NANTES

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Mannose derivatives useful for treating pathologies associated with adherent E. coli

Novel unnatural dipeptoids of .alpha.-substituted Trp-Phe derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, colorectal tumors, or as antipsychotics are disclosed. Further the compounds are antianxiety agents, antiulcer agents, antidepressant agents, and are agents useful for preventing the withdrawal response produced by chronic treatment or use followed by chronic treatment followed by withdrawal from nicotine, diazepam, alcohol, cocaine, caffeine, or opiods. Also disclosed are pharmaceutical compositions and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare pharmaceutical and diagnostic compositions.

Warner-Lambert Company

N-substituted cycloalkyl and polycycloalkyl .alpha.-substituted Trp-Phe- and phenethylamine derivatives